VVT Med Announces Debt Settlement and Equity Incentive Grants to Strengthen Capital Structure

VANCOUVER, BC, Aug. 21, 2026 /CNW/ -- VVT Med Inc. (TSXV: VVTM) ("VVT Med" or the "Company"), a developer of minimally invasive, non-thermal, non-tumescent solutions for venous disease, today announced proposed debt settlement transactions, together with grants of stock options and restricted share units to directors and employees.

Debt Settlement to Strengthen Capital Structure

VVT Med announces that it intends to enter into agreements with various vendors to settle a total of CAD$212,939.76 of outstanding indebtedness through the issuance of 586,096 common shares, of which 125,000 at a deemed price of CAD$0.56 per share and 461,096 at a deemed price of CAD$0.31 per share (the "Proposed Debt Settlement").

The issuance of shares pursuant to the Proposed Debt Settlement arrangement is subject to approval by the TSX Venture Exchange (the "TSXV"). The shares will be subject to a statutory hold period of four months and one day, in accordance with applicable securities laws and TSXV policies. Completion of the Proposed Debt Settlement remains conditional upon the execution of definitive agreements and receipt of final approval from the TSXV.

Equity Incentive Grants

The Company announces that it has granted 688,773 stock options ("Participant Options") to the Company's Advisory Board and to employees pursuant to the terms of the Company's stock option plan. Of this amount, 240,000 Participant Options were granted to the advisory board directors and the remaining 448,773 Participant Options were granted to employees. The Participant Options shall vest at a rate of 8.33% every quarter over a period of three years. All Participant Options shall have an exercise price of CAD$0.56 and shall expire five years after their grant.

In addition, the Company granted 912,519 Restricted Share Units ("Participant RSUs") to directors and employees pursuant to the terms of the Company's RSU plan. Of this amount, 792,519 Participant RSUs were granted to directors. The remaining 120,000 Participant RSUs were granted to employees.

Additional Corporate Information

For completeness, the Company notes that the management cease trade order previously issued in connection with the Company's financial reporting requirements was revoked on July 2, 2026, following the filing of the required records. The revocation order was issued by the British Columbia Securities Commission. The Company is not currently subject to the management cease trade order.

About VVT Med Inc. (VVTM)

VVT Medical develops, manufactures, and distributes minimally invasive, non-thermal, non-tumescent (NT-NT) solutions for the treatment of vein diseases, starting with varicose veins. VVT is one of the few FDA-cleared, standalone companies offering NT-NT varicose vein treatment technology. VVT's FDA-cleared and CE-marked catheter-based technologies, ScleroSafe^® and V-Block™, enable safe, office-based procedures with no anesthesia, no downtime, and minimal pain and side effects. Addressing the widest range of vein diameters, VVT's solutions empower patients by treating both the medical and aesthetic aspects of vein disease, while enabling physicians to deliver effective, efficient, and cost-saving treatments through proprietary, simultaneous sclerosant injection and blood aspiration. The Company's patented technology portfolio includes 55 patents from 14 patent families across 20 countries, providing broad global intellectual property protection through 2038. For more information, visit www.vvtmed.com.

Cautionary Note Regarding Forward-Looking Statements

This news release contains statements that constitute "forward-looking statements" or "forward-looking information" (collectively, "forward-looking information") under applicable securities laws. Such forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements, or developments to differ materially from those anticipated in such statements. Forward-looking information in this news release includes, but is not limited to, statements regarding the Proposed Debt Settlement, the execution of definitive debt settlement agreements, and the receipt of required TSXV approvals. Such statements reflect the current views of the Company and are not guarantees of future performance. They are based on a number of assumptions, including the Company's ability to execute the proposed transactions and obtain necessary approvals. The forward-looking information contained in this news release represents the Company's expectations as of the date hereof and is subject to change thereafter. Readers are cautioned not to place undue reliance on such information. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

This news release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States. The Company's securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE VVT MED INC.

Contact Information: [email protected]